Anthem Biosciences Limited is all set to launch its initial public offering (IPO) with the subscription window opening on July 14, 2025, and closing on July 16, 2025. The allotment is expected to be finalised by Thursday, July 17, 2025, and the company is scheduled to list on BSE and NSE on Monday, July 21, 2025.
Founded in 2006, Anthem Biosciences is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) with a strong emphasis on innovation and integrated services. Below is a detailed overview of the Anthem Biosciences IPO, along with key operational insights, financials, and risk factors.
Anthem Biosciences IPO Date
The key pointers for the Anthem Biosciences IPO dates are:
- Bidding Opening Date: July 14, 2025
- Bidding Closing Date: July 16, 2025
- Allotment Date: July 17, 2025
- Initiation of Refunds (in case of less or no allotment): July 18, 2025
- Shares Credited to Your Demat Account: July 18, 2025
- IPO Listing Date: July 21, 2025
- Listing on Exchange: BSE and NSE
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Anthem Biosciences IPO Issue Size
Anthem Biosciences’ IPO valuation, as denoted by the market capitalization, stood at ₹31,867 crores.
Here are the important Anthem Biosciences IPO details:
- Anthem Biosciences IPO Price Band: ₹540 to ₹570 per share
- Face Value: ₹2 per share
- Lot Size: 26 Shares
- Issue Size and Amount: 5.95 crore shares (amounting to ₹3,395 crores)
- OFS Size and Amount: 5.95 crore shares (amounting to ₹3,395 crores)
Anthem Biosciences IPO Proceeds Usage
The company will not receive any funds from the offer, as all proceeds will go directly to the selling shareholders. After deducting offer-related expenses and applicable taxes, the net proceeds will be retained by the respective selling shareholders.
Anthem Biosciences IPO Reservations
Anthem Biosciences IPO reservations to different investors are:
- For QIBs: Not more than 50% of the Net Issue
- For NIIs: Not less than 15% of the Net Issue
- For Retail Investors: Not less than 35% of the Net Issue
Anthem Biosciences IPO Shareholder Quota: There is no provision of shareholder quota in the red herring prospectus (RHP).
Anthem Biosciences IPO Lot Size
Anthem Biosciences IPO lot size is 26 shares, wherein bidding can be done in multiples. The minimum amount that each category of investor needs to bid in this IPO is:
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 26 | ₹14,820 |
| S-HNI | 14 | 364 | ₹2,07,480 |
| B-HNI | 68 | 1,768 | ₹10,07,760 |
Anthem Biosciences IPO Details: Promoter Holding
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj.
Viridity Tone LLP, Ganesh Sambasivam, K Ravindra Chandrappa, and Malay J Barua are some of the biggest selling shareholders in this IPO.
Anthem Biosciences IPO: Company Overview
Founded in 2006, Anthem Biosciences Limited is a research-driven company that provides end-to-end services in drug discovery, development, and manufacturing.
It operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), supporting pharmaceutical and biotech companies across the globe. The company produces a range of specialised fermentation-based active ingredients such as enzymes, probiotics, peptides, biosimilars, nutritional compounds, and vitamin analogues.
As of March 31, 2025, the company was handling 242 projects, including 68 in drug discovery and 13 focused on commercial manufacturing. It had a broad client base of over 550 in the CRDMO and specialty ingredients segments, spread across more than 44 countries, including the U.S., Europe, and Japan. Anthem currently holds eight patents (one in India and seven internationally), with 17 more patent applications under review.
As far as its operational efficiency is concerned, Anthem Biosciences got the highest ROE (20.8%), ROCE (26.9%), and EBITDA margin (36.8%) in the financial year 2024-25. It is better than the respective ratios of leading players in this industry, such as Syngene International, Sai Life Sciences, and Divi’s Laboratories.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Anthem Biosciences IPO: Financial Performance
Anthem Biosciences Limited’s key financials for different periods are as follows:
| Particulars (in ₹ Cr) | FY25 | FY24 | YoY Change |
|---|---|---|---|
| Operating Revenue | 1,844.55 | 1,419.37 | 30% |
| Profit After Tax | 451.26 | 367.31 | 23% |
| EBITDA | 683.78 | 519.96 | 32% |
| Net Worth | 2,409.86 | 1,924.66 | 25% |
| Assets | 2,807.58 | 2,398.11 | 17% |
| Total Borrowing | 108.95 | 232.53 | -53% |
- Anthem Biosciences’ revenue from operations grew by 30% YoY to ₹1,844.55 crores while its net profit also saw a jump of 23% to ₹451.26 crores in FY25.
- The EBITDA increased by 32% YoY to ₹683.78 crores, representing the growing core operating performance of the company.
- The assets increased by 17% YoY to ₹2,807.58 crores. In addition to this, borrowings reduced by 53% to ₹108.95 crores, which shows its better debt management practices.
Anthem Biosciences IPO Risk Factors
Anthem Biosciences IPO GMP is ₹119 as of July 10, 2025 (at 15:35). It is expected to list at a 20.88% gain at a price of ₹689. However, GMP is not a safe or assured criterion to bid for an IPO.
Anthem Biosciences Limited is exposed to various risk factors that can eventually affect its business and investors’ perception:
- Revenue Concentration: More than 81% of the revenue is derived from the CRDMO services, making the business sensitive to the overall outlook of the pharmaceutical industry.
- Project Delays: Over 70% of the revenue comes from developmental and commercial manufacturing projects, and any failure to execute these projects can impact the business.
- Technological Change: The pharmaceutical industry is growing with massive technological advancements, which require heavy investment and the development of new technologies to stay relevant.
- Customer Risk: The top 5 customers hold over 70% share in the revenue, and there is a risk of losing out on such clients, which can hugely impact the financial performance.
- Heavy Regulations: Failure to meet the pharmaceutical industry’s regulations in Indian and global markets can have an adverse impact on the operations.
Anthem Biosciences IPO Details: Contact Details
Here are details of the registered address and registrar name of Anthem Biosciences Limited:
- Registered Office Address: Anthem Biosciences Ltd, No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099
- Company Website: https://www.anthembio.com/
- Registrar Name: Kfin Technologies Limited
For all the insights on Anthem Biosciences IPO and detailed expert advice, you can download the SMC ACE App or visit the SMC telegram channels. Take smart decisions and apply for Anthem Biosciences IPO easily on the SMC ACE App by opening free demat account now.
Frequently Asked Questions – FAQs
1. Which dates are crucial for Anthem Biosciences’ initial public offering?
Monday, July 14, 2025, marks the start of the Bid/Offer of Anthem Biosciences IPO, which ends on Wednesday, July 16, 2025.
2. What is the lot size of the Anthem Biosciences IPO?
The Anthem Biosciences IPO lot size is 26, and ₹14,820 is the minimum amount retail investors need to apply.
3. What is the price of Anthem IPO?
Anthem Biosciences IPO price band is fixed at ₹540 to ₹570 per share. Its pre-IPO PE ratio is 70.62, which is lower than the industry average PE ratio of 81.06, signalling an undervalued opportunity.
References:
https://www.sebi.gov.in/filings/public-issues/jul-2025/anthem-biosciences-limited-rhp_95139.html
https://www.investorgain.com/gmp/anthem-biosciences-ipo-gmp/1317/
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
